Harrow Heads Into Earnings With Bears Firmly Dug In

HROW enters its August 10 print carrying one of the most crowded short positions in the pharmaceutical universe — and the borrow market has tightened sharply in the past week, adding pressure to both sides of the trade.

Short interest is running at 18.4% of the free float, placing HROW in the 4th percentile for short score rank across ORTEX's coverage. That's not a marginal bearish tilt — it's a structural overhang. The short score has been climbing steadily, reaching 79.1 on August 6, its highest reading in at least ten days. Availability has tightened to 25.7%, dropping 23% in a single week, which means roughly three of every four shares available for borrowing are already lent out. Despite that squeeze on the lending pool, borrow costs remain surprisingly cheap at 0.74% — a disconnect that suggests the short side is well-established rather than freshly building. The stock recovered 4.3% over the past week to close at $40.44, but is still down 12.4% over the past month.

Options traders are not panicking into the print. The put/call ratio at 0.20 is barely above its 20-day average of 0.19 — actually close to the 52-week low of 0.16, far below the year-high of 0.44. That reading sits 1.4 standard deviations above the recent mean, but in absolute terms it reflects call-heavy positioning, the opposite of defensiveness. Investors with options exposure are leaning toward upside, not protection.

The bull-bear debate centers on whether HROW's revenue recovery is real and durable. Bulls point to Harrow's growth in the US ophthalmic pharmaceutical market, an ambitious $250M quarterly revenue target for 2027, and a factor score that ranks in the 92nd percentile for EPS surprise — meaning the company has a strong historical track record of beating estimates. Bears have a specific near-term grievance: IHEEZO lost its pass-through reimbursement status in the surgical setting in April, triggering a distributor destocking cycle and an anticipated price reset. High-deductible plan headwinds also pressured Vevye sales in Q1. Analyst coverage remains broadly constructive — BTIG reiterated Buy with a $63 target as recently as July 21, and Cantor Fitzgerald holds an Overweight rating, though it has trimmed its target twice in 2026, from $94 down to $88. The consensus mean target of $67.75 implies roughly 68% upside from the current price, a gap that reflects either significant undervaluation or the market's scepticism about near-term execution.

One ownership detail stands out. In mid-May, following the prior quarter's sharp selloff — the stock fell roughly 22% the day after the Q1 print — CEO Mark Baum bought 10,000 shares at $30.20 and CFO Andrew Boll purchased 3,500 shares at $29.90. Two directors also bought in the same week. That cluster of insider buying near what proved to be a trough is the clearest signal that management believes the dislocation was overdone. Opaleye Management, previously a 10% owner, sold down heavily in February and March at prices around $39-54, reducing its stake to 6.4% — a reminder that not all insiders read the story the same way. The earnings report will test whether management's confidence in an H2 recovery is matched by the underlying revenue and margin data, or whether bears sitting on 18% of the float get another chance to cover on a negative reaction.